Literature DB >> 19942238

Negative correlation between neuropeptide Y/agouti-related protein concentration and adiponectinemia in nonalcoholic fatty liver disease obese adolescents submitted to a long-term interdisciplinary therapy.

Aline de Piano1, Lian Tock, June Carnier, Lila M Oyama, Cláudia M Oller do Nascimento, Aniella C Martinz, Denis Foschini, Priscila L Sanches, Regina M Y Ernandes, Marco Túlio de Mello, Sérgio Tufik, Ana R Dâmaso.   

Abstract

The complexity pathogenesis in the nonalcoholic fatty liver disease (NAFLD) involves an interplay between adipokines and neuroendocrine regulation of energy balance, including the role of neuropeptide Y (NPY)/agouti-related protein (AgRP) system. The first aim of this study was to assess the effect of long-term interdisciplinary intervention on NAFLD in obese adolescents, and the second objective was to establish the relationship between NPY/AgRP ratio and adiponectinemia. Fifty-five postpuberty obese adolescents were submitted to interdisciplinary intervention. The group was divided between subjects with and without NAFLD (n = 19 and 36, respectively). Blood samples were collected to measure glycemia, hepatic transaminases, lipid profile, insulin resistance, and sensitivity. Adiponectin, NPY, and AgRP concentrations were measured by enzyme-linked immunosorbent assay. Food intake was measured using 3-day diet records. It was observed at baseline that important clinical parameters including body weight, body mass index, visceral fat, homeostasis model assessment of insulin resistance, quantitative insulin sensitivity check index, triglycerides, very low-density lipoprotein cholesterol, and hepatic transaminases were more altered in NAFLD patients. After the intervention, these parameters, total energy, and macronutrient intake were reduced significantly in both groups. The most important finding was the positive correlation between AgRP and visceral fat in all patients and the negative correlation between NPY/AgRP and adiponectinemia only in NAFLD obese adolescents. The NAFLD patients presented more altered clinical parameters than the non-NAFLD subjects, including the negative correlation between adiponectinemia and NPY/AgRP. These results suggested that NAFLD obese adolescents presented an inflammatory profile that can influence the neuroendocrine regulation of energy balance, suggesting an additional impairment in the weight loss therapy.

Entities:  

Mesh:

Substances:

Year:  2009        PMID: 19942238     DOI: 10.1016/j.metabol.2009.09.003

Source DB:  PubMed          Journal:  Metabolism        ISSN: 0026-0495            Impact factor:   8.694


  9 in total

1.  The role of PAI-1 and adiponectin on the inflammatory state and energy balance in obese adolescents with metabolic syndrome.

Authors:  Flavia Campos Corgosinho; Aline de Piano; Priscila L Sanches; Raquel M Campos; Patricia L Silva; June Carnier; Lila M Oyama; Lian Tock; Sergio Tufik; Marco T de Mello; Ana R Dâmaso
Journal:  Inflammation       Date:  2012-06       Impact factor: 4.092

2.  Glp-1 analog, liraglutide, ameliorates hepatic steatosis and cardiac hypertrophy in C57BL/6J mice fed a Western diet.

Authors:  Jamie E Mells; Ping P Fu; Shvetank Sharma; Darin Olson; Lihong Cheng; Jeffrey A Handy; Neeraj K Saxena; Dan Sorescu; Frank A Anania
Journal:  Am J Physiol Gastrointest Liver Physiol       Date:  2011-10-28       Impact factor: 4.052

3.  Neuropeptide Y levels are associated with nutritional status and cardiovascular events in adults with chronic kidney disease.

Authors:  L Lu; Y-C Zou; M Wang; Y-F Huang; D-X Chen; L-B Wei
Journal:  Eur J Clin Nutr       Date:  2015-04-29       Impact factor: 4.016

4.  Metabolic predictors for early identification of fatty liver using doppler and B-mode ultrasonography in overweight and obese adolescents.

Authors:  Mine Ozkol; Betül Ersoy; Erhun Kasirga; Fatma Taneli; Işil Esen Bostanci; Bayram Ozhan
Journal:  Eur J Pediatr       Date:  2010-05-25       Impact factor: 3.183

5.  Long-term effects of aerobic plus resistance training on the metabolic syndrome and adiponectinemia in obese adolescents.

Authors:  Marco Túlio de Mello; Aline de Piano; June Carnier; Priscila de Lima Sanches; Fabíola Alvise Corrêa; Lian Tock; Regina M Y Ernandes; Sérgio Tufik; Ana R Dâmaso
Journal:  J Clin Hypertens (Greenwich)       Date:  2010-11-08       Impact factor: 3.738

6.  Cut-Off Values of Visceral Adiposity to Predict NAFLD in Brazilian Obese Adolescents.

Authors:  Ana Paula Grotti Clemente; Bárbara Dal Molin Netto; Aline di Piano Ganen; Lian Tock; Danielle Arisa Caranti; Marco Túlio de Mello; Sergio Tufik; Ana R Dâmaso
Journal:  J Nutr Metab       Date:  2013-12-07

7.  Long-term interdisciplinary therapy reduces endotoxin level and insulin resistance in obese adolescents.

Authors:  Fábio S Lira; Jose C Rosa; Gustavo D Pimentel; Ronaldo V Santos; June Carnier; Priscila L Sanches; Aline de Piano; Claudio T de Souza; Lian Tock; Sergio Tufik; Marco T de Mello; Marília Seelaender; Claudia M Oller do Nascimento; Lila M Oyama; Ana R Dâmaso
Journal:  Nutr J       Date:  2012-09-18       Impact factor: 3.271

8.  Multidisciplinary approach to the treatment of obese adolescents: effects on cardiovascular risk factors, inflammatory profile, and neuroendocrine regulation of energy balance.

Authors:  Ana Raimunda Dâmaso; Aline de Piano; Raquel Munhoz da Silveira Campos; Flávia Campos Corgosinho; Wolfgang Siegfried; Danielle Arisa Caranti; Deborah Cristina Landi Masquio; June Carnier; Priscila de Lima Sanches; Patrícia Leão da Silva; Cláudia Maria Oller Nascimento; Lila Missae Oyama; Alexandre Dâmaso Aguilera Dantas; Marco Túlio de Mello; Sergio Tufik; Lian Tock
Journal:  Int J Endocrinol       Date:  2013-10-27       Impact factor: 3.257

9.  [Waist circumference as a marker for screening nonalcoholic fatty liver disease in obese adolescents].

Authors:  Ana Paula Grotti Clemente; Bárbara Dal Molin Netto; Joana Pereira de Carvalho-Ferreira; Raquel Munhoz da Silveira Campos; Aline de Piano Ganen; Lian Tock; Marco Túlio de Mello; Ana Raimunda Dâmaso
Journal:  Rev Paul Pediatr       Date:  2015-12-31
  9 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.